Navigation Links
Stereotaxis Appoints Industry Veteran as Head of EMEA Sales and Operations
Date:10/28/2010

ST. LOUIS, Oct. 28 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced today the appointment of Pierre Rivaux as Vice President, Europe, Middle East, Africa (EMEA) to lead the Company's EMEA operations and sales efforts in continuing to drive increased capital sales and utilization of its Niobe® Remote Magnetic Navigation System and Odyssey™ system. Mr. Rivaux will report directly to Michael P. Kaminski, President and CEO of Stereotaxis.

"Pierre brings over 20 years of international sales and broad executive experience in the medical device industry that enhances Stereotaxis' focus on driving future sales growth in Europe and other key international markets," said Mr. Kaminski. "Pierre's extensive experience in Europe, strong leadership and expertise in selling high-tech medical/surgical disposables and capital equipment, as well as in building effective international teams and global sales operations will be tremendous assets as we continue to execute on our strategy to drive commercial success of our innovative technology platforms, Niobe and Odyssey."

Mr. Rivaux previously held various management positions at Intuitive Surgical, including Vice President of International Sales & Marketing, President and CEO of Intuitive Surgical SA France and CEO of Intuitive Surgical Sarl in Switzerland, where he was responsible for implementing a new sales, marketing and finance organization focused on Europe (direct and distribution), Middle East, Africa, India, Asia and Latin America. Prior to that, from 2000 to 2004, Mr. Rivaux held management positions across Europe with Tyco Healthcare, most recently serving as Vice President of Central Europe. He was also the President and CEO of Tyco Healthcare France. Before that, he worked at Kendall S.A., most recently as President, CEO and General Manager of Kendall Incontinence. He earned his graduate degree at the Lille Graduate School of Management in 1985.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe® Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure.

Stereotaxis' Odyssey™ portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world. Odyssey™ Vision integrates data for magnetic and standard interventional labs, enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey™ Enterprise Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed.  Odyssey™ then enables hospitals to efficiently share live and recorded clinical data anywhere around the world to maximize referrals and promote collaboration.

The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products in the marketplace, the effect of global  economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereotaxis Market Leadership Reinforced in Core Curriculum and Symposium Presentations at Heart Rhythm 2008
2. Stereotaxis Receives Commitment to Increase and Extend Its Credit Facility With Silicon Valley Bank
3. Stereotaxis Announces Public Offering of Common Stock
4. Stereotaxis Announces Pricing of $26 Million Common Stock Offering
5. Stereotaxis Announces Underwriters Exercise of Over-Allotment Option
6. Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter
7. Stereotaxis System Procedure Featured on NBCs The TODAY Show
8. Stereotaxis is Notified of the FDA Approval of an Additional Magnetic Irrigated Catheter
9. Stereotaxis Installs First System in Taiwan
10. Stereotaxis Updates Progress on Major Clinical Initiative Related to Electrophysiology (EP) Treatment of Ventricular Tachycardia
11. Stereotaxis Announces Vdrive(TM), a New Technology for Remote Navigation of Diagnostic Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Feb. 22, 2017  Corin Group announced today the ... used to treat patients with both a massive rotator ... The condition, known as cuff tear arthropathy, causes pain ... The Humelock Reversed Shoulder System, which was ... company based near Lyon, France , ...
(Date:2/22/2017)... Research and Markets has announced the addition of the ... to their offering. ... Dermatological conditions are one of the most ... US population suffers from at least one active skin condition. ... has remained saturated with established and generic products. However, the ...
(Date:2/22/2017)... 22, 2017 Research and Markets has ... by Drug Molecule (Biologic, Small Molecule Drugs), By Route of ... Blockers) Outlook 2022" report to their offering. ... The global psoriasis ... 2016-2022 This report provides a detailed analysis of ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five percent ... those report that family members or friends have also commented about their poor ... loss wear hearing aids. One reason, suggested by 89 percent of American respondents, ...
(Date:2/22/2017)... ... February 22, 2017 , ... Super-Sod will attend the ... event in Athens, Georgia. , A shift from Super-Sod’s simple Athens Home Show booth ... For the booth, grass seed plant manager Chris Roquemore constructed furniture from recycled pallet ...
(Date:2/22/2017)... Troy, NY (PRWEB) , ... February 22, 2017 , ... ... effort — especially for hospitals and health systems. Smith & Jones’ delves into this ... In this episode, President of Smith & Jones David Vener meets up with social ...
(Date:2/22/2017)... ... ... BrightStar Care Charleston , a home care and medical staffing agency, ... Center on Aging’s Senior Expo on Thursday, March 23, 2017, at the Omar ... in our community. We are thrilled to participate in this event because we believe ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a ... that the patient context (age, illness and life choices) should be dissociated from ... occurrence. In addition, all too often, studies regarding health system performance ...
Breaking Medicine News(10 mins):